Journal of Pharma Creations (JPC)

JPC |Vol.12 | Issue 3 | Jul - Sept -2025

www.pharmacreations.com

ISSN: 2348-6295

DOI : https://doi.org/10.61096/jpc.v12.iss3.2025.177-179

Review

Challenges Faced by Indian Pharma Companies in PIC/S Regulations

Tejasree. K[1], Dr. Rohini reddy Shimmula[2], Dr. Swetha Medishetti[*3]

[1]M.Pharm Student, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Affiliated to Osmania University, Tarnaka, Secunderabad, Telangana 500017
[2]Associate Professor, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Affiliated to Osmania University, Tarnaka, Secunderabad, Telangana 500017
[3]Associate Professor & Head, Department of Regulatory Affairs, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Affiliated to Osmania University, Tarnaka, Secunderabad, Telangana 500017*

*Author for Correspondence: Dr. M. Swetha
Email: swethasnvpm@gmail.com

Published on: 27 Sept 2025

Published by:
Futuristic Publications

Abstract

Pharmaceutical Inspection Co-operation Scheme (PIC/S) guidelines represent a global standard for Good Manufacturing Practices (GMP), aimed at harmonizing inspection procedures and ensuring the quality, safety, and efficacy of pharmaceutical products. For Indian pharmaceutical companies, which play a pivotal role in the global supply chain, aligning with PIC/S regulations is critical yet fraught with multiple challenges. This article examines the multifaceted obstacles faced by Indian pharma firms in achieving PIC/S compliance, such as infrastructural gaps, regulatory misalignment, workforce skill deficits, and financial constraints. The paper also explores policy-level interventions and strategic solutions to bridge these gaps and enhance India's position in the global pharmaceutical regulatory landscape.

Keywords: PIC/S, GMP compliance, Indian pharmaceutical industry, regulatory challenges, quality assurance, global harmonization, drug manufacturing standards.

INTRODUCTION

India is globally recognized as the “pharmacy of the world,” supplying affordable and quality generic medicines to over 200 countries. Despite this stature, Indian pharmaceutical companies often struggle to comply with stringent international regulatory norms, particularly those set by the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Established to harmonize GMP standards across member countries, PIC/S has emerged as a benchmark for regulatory compliance in pharmaceutical manufacturing.

As India aspires for membership in PIC/S, the nation's pharmaceutical companies are under increased scrutiny to elevate their manufacturing standards to meet the global benchmark. This article identifies and elaborates on the major challenges that Indian pharma companies face in aligning with PIC/S norms.[1]

METHODOLOGY

This article adopts a qualitative research approach, analyzing secondary data from:

- Regulatory reports (WHO, CDSCO, USFDA, EMA)
- Industry white papers
- Peer-articleed journal articles
- News reports and expert opinions
- Government publications (MoHFW, Department of Pharmaceuticals)

The data was critically examined to extract recurring themes, categorize challenges, and highlight industry practices affecting PIC/S compliance. [1-2]

DISCUSSIONS

Regulatory Misalignment

India's primary drug regulator, the Central Drugs Standard Control Organization (CDSCO), follows Schedule M of the Drugs and Cosmetics Act, which is not fully harmonized with PIC/S standards. This misalignment leads to confusion and difficulty for pharma exporters who must meet multiple sets of regulations simultaneously.[3]

Infrastructural Deficiencies

Many small- and medium-sized pharmaceutical enterprises (SMEs) lack modern manufacturing infrastructure required to comply with PIC/S standards, including:

- HVAC systems
- Data integrity-compliant software
- Automated quality control systems
- Cleanroom technology

The high capital expenditure required to upgrade facilities often acts as a deterrent, especially for domestic-focused companies.[4]

Workforce Competency

There is a critical skills gap in GMP compliance among the Indian pharmaceutical workforce. Key issues include:

- Inadequate training on PIC/S norms
- Poor documentation practices
- Lack of familiarity with electronic data integrity and audit trails

This results repeat regulatory observations, especially during international inspections (e.g., by USFDA or EMA). [5]

Financial Constraints

Compliance with PIC/S regulations involves significant investment in:

- Infrastructure modernization
- Quality management systems
- Human resource development

Many SMEs lack the financial resilience to make these investments, resulting in partial or non-compliance.[6]

Lack of Regulatory Support and Incentives

There is limited regulatory or financial support from the government for companies trying to transition to international standards. Unlike other countries, India does not yet provide structured subsidies, tax incentives, or soft loans specifically for GMP compliance.[7]

Risk of Market Exclusion

Non-compliance with PIC/S norms leads to:

- Bans or import alerts from foreign regulatory agencies
- Loss of credibility in global markets
- Delayed product launches in regulated markets

This negatively impacts export revenues and undermines the reputation of the Indian pharma sector.[8]

CONCLUSION

Indian pharmaceutical companies face a complex set of challenges in complying with PIC/S regulations, stemming from regulatory misalignment, infrastructural and financial barriers, and workforce limitations. Addressing these challenges requires a multi-pronged approach involving government support, industry collaboration, and educational reforms. A strategic policy roadmap focusing on GMP harmonization, infrastructural upgradation, and regulatory training will be crucial for enabling Indian pharma's seamless integration into the global regulatory ecosystem.

REFERENCES

1. CDSCO Guidelines and Notices – Ministry of Health & Family Welfare, Government of India.
2. Pharmaceutical Inspection Co-operation Scheme (PIC/S) Official Website – https://picscheme.org
3. USFDA Warning Letters Database – https://www.fda.gov
4. "GMP Compliance Challenges in Indian Pharmaceutical Industry" – *Journal of Regulatory Science*, 2024.
5. WHO GMP Guidelines – World Health Organization.
6. "The Road to PIC/S: A Strategic Imperative for India" – Confederation of Indian Industry (CII) Report, 2023.
7. Department of Pharmaceuticals Annual Report – Government of India, 2024.
8. Ernst & Young, "Global Pharma Compliance Survey," 2023.